Characteristics of Patients with Crohn's Disease With or Without Perianal Fistulae in the CorEvitas Inflammatory Bowel Disease Registry

被引:4
|
作者
Fan, Yanni [1 ]
Delgado-Aros, Silvia [2 ]
Valdecantos, Wendell C. [1 ]
Janak, Jud C. [3 ]
Moore, Page C. [3 ]
Crabtree, Margaux M. [3 ]
Stidham, Ryan W. [4 ]
机构
[1] Boehringer Ingelheim Pharmaceut Inc, 900 Ridgebury Rd, Ridgefield, CT 06877 USA
[2] Boehringer Ingelheim Int GmbH, Binger Str 173, D-55218 Ingelheim, Germany
[3] CorEvitas LLC, 1440 Main St, Waltham, MA 02451 USA
[4] Univ Michigan, Dept Internal Med, Div Gastroenterol & Hepatol, 500 S State St, Ann Arbor, MI 48109 USA
关键词
Crohn's disease; Perianal fistula; CorEvitas IBD Registry; INFLIXIMAB; DIAGNOSIS;
D O I
10.1007/s10620-022-07491-y
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background There are limited real-world data characterizing perianal fistulae in patients with Crohn's disease (CD). Aim To describe characteristics of patients with CD with and without perianal fistulae. Methods In this cross-sectional study, characteristics, treatment history, and health outcomes of patients with CD enrolled in the CorEvitas IBD Registry were described according to perianal fistula status (current/previous or none). Results Eight hundred and seventy-eight patients were included. Compared with patients with no perianal fistulae (n = 723), patients with current/previous perianal fistulae (n = 155) had longer disease duration since CD diagnosis (mean 16.5 vs 12.3 years; difference 4.3 years; 95% CI, 2.0, 6.6) and fewer had Harvey-Bradshaw Index scores indicative of remission (0-4, 56.8% vs 69.6%; difference - 12.9%; 95% CI, - 21.6, - 4.2). More patients with current/previous fistulae reported a history of IBD-related emergency room visits (67.7% vs 56.1%; difference 11.6%; 95% CI, 3.4, 19.8), hospitalizations (76.1% vs 58.4%; difference 17.7%; 95% CI, 10.1, 25.4), and surgeries (59.4% vs 27.7%; difference 31.7%; 95% CI, 23.3, 40.1), and a history of treatment with tumor necrosis factor inhibitors (81.3% vs 60.7%; difference 20.6%; 95% CI, 13.5, 27.7), immunosuppressants (51.6% vs 31.2%; difference 20.4%; 95% CI, 11.9, 29.0), and antibiotics (50.3% vs 23.7%; difference 26.6%; 95% CI, 18.2, 35.1) than patients without perianal fistulae. Conclusions Patients with CD with current/previous perianal fistulae have more symptomatic experiences of disease, higher medication use, hospitalization rates, and emergency room visits than patients without perianal fistulae. Interventions to prevent/reduce risk of developing fistulae may help improve outcomes in CD. [GRAPHICS] .
引用
收藏
页码:214 / 222
页数:9
相关论文
共 50 条
  • [41] Perianal Crohn's disease
    Morales, MS
    Marini, M
    Caminero, M
    Caglio, P
    INTERNATIONAL JOURNAL OF DERMATOLOGY, 2000, 39 (08) : 616 - 618
  • [42] Characteristics of CMV enterocolitis in patients with or without inflammatory bowel disease
    Seo, A. Young
    Shin, Cheol Min
    Choi, Young Hoon
    Im, Jong Pil
    Lee, Dong Ho
    Kim, Nayoung
    Park, Youngsoo
    Yoon, Hyuk
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2013, 28 : 119 - 119
  • [43] Perianal Crohn's disease
    Sanchez, V. Garcia
    Flores, E. Iglesias
    REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS, 2007, 99 (07) : 420 - 420
  • [44] Perianal Crohn's disease
    ODonoghue, DP
    Hyland, JMP
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 1997, 9 (03) : 235 - 236
  • [45] Perianal Crohn's Disease
    Lightner, Amy L.
    DISEASES OF THE COLON & RECTUM, 2020, 63 (08) : 1023 - 1026
  • [46] A higher prevalence of human papillomavirus in patients with perianal fistulizing Crohn's disease compared to patients with anorectal fistula without Crohn's disease
    Boarini, L. Rodrigues
    Sobrado, C. W., Jr.
    Facanali, C. B. G.
    Queiroz, N. S. F.
    Albuquerque, I. C.
    Boarini, P.
    Boarini, M. R.
    Borba, M. R.
    Nahas, S. C.
    Cecconello, I.
    JOURNAL OF CROHNS & COLITIS, 2021, 15 : S563 - S563
  • [47] Pediatric perianal Crohn's disease without luminal inflammation
    Augustine, M.
    Williams, K. L.
    Altun, O.
    Gremse, D.
    AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 2024, 367 : S242 - S242
  • [48] Pharmacogenetics of inflammatory bowel disease: a focus on Crohn's disease
    Rufini, Sara
    Ciccacci, Cinzia
    Novelli, Giuseppe
    Borgiani, Paola
    PHARMACOGENOMICS, 2017, 18 (11) : 1095 - 1114
  • [49] Colitis and Crohn's Foundation (India): a first nationwide inflammatory bowel disease registry
    Sood, Ajit
    Kaur, Kirandeep
    Mahajan, Ramit
    Midha, Vandana
    Singh, Arshdeep
    Sharma, Sarit
    Puri, Amarender Singh
    Goswami, Bhabhadev
    Desai, Devendra
    Pai, C. Ganesh
    Peddi, Kiran
    Philip, Mathew
    Kochhar, Rakesh
    Nijhawan, Sandeep
    Bhatia, Shobna
    Rao, N. Sridhara
    INTESTINAL RESEARCH, 2021, 19 (02) : 206 - 216
  • [50] Patients' Perspectives, Experiences, and Concerns With Crohn's Perianal Fistulae: Qualitative Insights From Crohn's Disease Social Media Platforms
    Khalil, Carine
    Van Deen, Welmoed
    Dupuy, Taylor
    Syal, Gaurav
    Cazzetta, Susan E.
    Nazarey, Pradeep P.
    Almario, Christopher V.
    Spiegel, Brennan
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2021, 116 : S1364 - S1364